| Briefing Date: | 09/28/2001 |
| Topic: | Immunization Safety Review: Thimerosal - Containing Vaccines and Neurodevelopmental Disorders |
THE NATIONAL ACADEMIES
Institute of Medicine
Board on Health Promotion and Disease Prevention
Immunization Safety Review Committee
*****
Congressional Briefing
Friday, September 28, 2001 -- 3:30 p.m.
2157 Rayburn House Office Building
on
Immunization Safety Review:
Thimerosal - Containing Vaccines and Neurodevelopmental Disorders
by
Joshua Cohen, Ph.D., Senior Research Associate, Harvard Center for Risk Analysis, Harvard School of Public Health and Member, Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine
Rebecca Parkin, Ph.D., Associate Research Professor, Department of Occupational & Environmental Health, School of Public Health and Health Services, George Washington University and Member, Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine
Bennett Shaywitz, M.D., Professor of Pediatrics and Neurology, Co-Director, Yale Center for the Study of Learning and Attention, and Member, Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine
A standing committee of the Institute of Medicine has been charged with assessing hypothetical links between vaccines and various health problems. This second in a series of reports, Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders, examines whether thimerosal, an organic mercury compound, that was, but is no longer, a preservative in vaccines recommended for immunization of children six years and under, may have caused neuro- developmental disorders.
This briefing was for members of Congress and congressional staff only. The report was publicly released on October 1, 2001 and is available, in its entirety, through the Web site of the National Academies Press.
|
|
Subscribe to e-newsletters |
Feedback | Back to Top